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ABSTRACT
MXD1 is a protein that interacts with MAX, to form a repressive transcription 
factor. MXD1-MAX binds E-boxes. MXD1-MAX antagonizes the transcriptional 
activity of the MYC oncoprotein in most models. It has been reported that MYC 
overexpression leads to augmented RNA synthesis and ribosome biogenesis, 
which is a relevant activity in MYC-mediated tumorigenesis. Here we describe that 
MXD1, but not MYC or MNT, localizes to the nucleolus in a wide array of cell lines 
derived from different tissues (carcinoma, leukemia) as well as in embryonic stem 
cells. MXD1 also localizes in the nucleolus of primary tissue cells as neurons and 
Sertoli cells. The nucleolar localization of MXD1 was confirmed by co-localization 
with UBF. Co-immunoprecipitation experiments showed that MXD1 interacted with 
UBF and proximity ligase assays revealed that this interaction takes place in the 
nucleolus. Furthermore, chromatin immunoprecipitation assays showed that MXD1 
was bound in the transcribed rDNA chromatin, where it co-localizes with UBF, but 
also in the ribosomal intergenic regions. The MXD1 involvement in rRNA synthesis 
was also suggested by the nucleolar segregation upon rRNA synthesis inhibition 
by actinomycin D. Silencing of MXD1 with siRNAs resulted in increased synthesis 
of pre-rRNA while enforced MXD1 expression reduces it. The results suggest a new 
role for MXD1, which is the control of ribosome biogenesis. This new MXD1 function 
would be important to curb MYC activity in tumor cells.
INTRODUCTION
MXD1 (also known as MAD1) is a transcription 
factor belonging to the MXD family of proteins [1]. 
The MXD family (composed of MXD1, MXI1/MXD2, 
MXD3, MXD4 and MNT) is part of the MYC-MAX-
MXD network of transcription factors. These factors 
contain the b-HLH-LZ domain by which they bind to 
E-boxes in the promoter of their target genes to regulate 
their transcription [2–4].Whereas MYC-MAX activates 
transcription, MXD1-MAX represses transcription 
forming complexes with histone deacetylases. Therefore, 
MXD1 acts as antagonist of MYC transcriptional activity 
[5–7]. Conversely to MYC, MXD1 is readily expressed 
in resting and differentiated cells [6, 8, 9]. Moreover, 
MXD1 inhibits cell proliferation and antagonize MYC 
transforming activity [10–12].
The nucleolus is the nuclear factory for rRNA 
synthesis, posttranscriptional processing of pre-rRNA 
and assembly of preribosomal particles. It is organized 
around clusters of tandem repeats of RNA genes (rDNA) 
that encode the rRNAs 28S, 18S and 5.8S. The nucleolar 
structure, composed of fibrillar centers (FCs), dense 
fibrillar component (DFC) and granular component 
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(GC), reflects the sequential steps of ribosome biogenesis 
[13–15]. The FC concentrates components of the 
transcription machinery, such as RNA polymerase I and 
UBF (Upstream Binding Factor), an essential transcription 
factor of ribosomal genes [16]. The DFC partially 
surrounds FCs and contains transcriptionally active 
ribosomal genes and numerous RNA-binding proteins. 
RNA pol I transcription takes place in the FCs and in 
the DFC, with further posttranscriptional processing of 
pre-rRNA occurring within the DFC to give rise to the 
mature rRNAs [17, 18]. The GC is where the 40S and 60S 
ribosome subunits are assembled [19, 20].
MXD1 was described as nuclear in fibroblasts [1] 
and quiescent keratinocytes [21], but the subcellular 
localization of endogenous MXD1 is unknown for most 
cell types. Here we report that MXD1 localizes in the 
cell nucleolus and describe an interaction of MXD1 with 
UBF. In addition, we show that MXD1 binds to rDNA and 
regulates rDNA transcription.
RESULTS
MXD1 localization in the nucleolus
 We performed immunofluorescence studies in 
proliferating embryonic stem cells HS181, mesenchymal 
stem cells MSC-3H, myeloid leukemia K562 cells, 
embryonic kidney HEK293T cells, and cervical cancer 
HeLa cells. Although it is reported that MXD1 is mostly 
expressed in quiescent cells or differentiated cells, 
we found low but detectable MXD1 protein levels in 
proliferating cells of the above cell lines (Figure 1A), 
although serum deprivation resulted in increased MXD1 
expression, as described [22] (Figure 1A). We chose 
some of these cell lines with higher MXD1 expression to 
study its subcellular localization. As shown in Figure 1B, 
MXD1 was localized in the nucleus in all cell lines but, 
surprisingly, it was also concentrated in the nucleolus in 
a relevant proportion of cells (70% to 100% depending 
on the cell line). The nucleolar distribution of MXD1 was 
confirmed by its co-localization with UBF (Figure 1B), 
a nucleolar marker of FCs [13, 23]. The nucleolar 
localization for MXD1 is so far unreported and we set 
out to confirm this. Analysis of the fluorescence intensity 
profiles of UBF and MXD1 in cell lines and neurons 
demonstrated this co-localization (Supplementary 
Figure S1). We also asked if the subnuclear localization 
of MXD1 observed in cells in culture also occurred in 
primary tissue cells. We analysed by immunofluorescence 
Sertoli and germinal cells from rat seminiferous tube and 
rat sensory ganglion neurons. MXD1 was concentrated 
in the nucleolus, with a weaker nucleoplasmic signal, 
in post-mitotic Sertoli cells and neurons (Figure 2A). 
The nucleolar localization of MXD1 was confirmed 
in preparations co-stained with propidium iodide 
(Figure 2A), and its preferential concentration in FCs 
of neurons was demonstrated by co-localization with 
UBF (Figure 1A, lower panel). Moreover, immunogold 
electron microscopy confirmed the localization of 
MXD1 in FCs and associated DFC of the neuronal 
nucleolus (Figure 2B). To further confirm this subnuclear 
distribution, we transfected HeLa cells with a GFP-MXD1 
construct. As controls, we also transfected a GFP-MNT 
and GFP constructs. Following 24 h of transfection, the 
transfected GFP-MXD1 protein was diffusely distributed 
in the nucleoplasm, but concentrated in the nucleolus 
(Figure 3A). The nucleolar localization of exogenous 
GFP-MXD1 was confirmed by immunofluorescence with 
the anti-UBF antibody, showing the co-localization of 
GFP and UBF signals (Figure 3B). 
We next studied whether the nucleolar distribution 
of MXD1 was extensible to MYC and another member 
of the MXD family as MNT. In sharp contrast to MXD1, 
both MYC and MNT were present in the nucleoplasm 
but excluded from the UBF-immunolabeled nucleoli in 
most cells (Figure 4). Fluorescence intensity line profiles 
confirmed the absence of MYC and MNT in the nucleolus 
(Supplementary Figure S2). Moreover, overexpressed MNT 
did not accumulate in the nucleolus, as shown in HeLa cells 
transfected with a GFP-MNT construct (Figure 3A).
The co-localization of MXD1 and UBF in the FCs 
opened the possibility that MXD1 might be regulating 
rDNA transcription. To test this, we treated HS181 and 
MSC-3H cells with actinomycin D at low concentration 
(50 ng/ml for 1 h), and performed co-immunostaining for 
MXD1 and UBF. Under these conditions, actinomycin 
D inhibits RNA pol I but not RNA pol II and RNA 
pol III [24, 25]. We also treated rats systemically 
with actinomycin (300 µg/kg for 3 h) and analysed 
the nucleolar reorganization in sensory neurons from 
trigeminal ganglia. Interestingly, we found that RNA 
pol I inhibition interfered with the nucleolar targeting 
of MXD1 in all cases, as a MXD1-free nucleolar area 
appeared after treatment with actinomycin D, meanwhile 
the nucleoplasmic signal of MXD1 remained unchanged 
(Figure 5). In MSC-3H cells and sensory neurons, MXD1 
was segregated at the nucleolar periphery, forming typical 
perinucleolar caps or rings in confocal images (Figure 5) 
[26]. This effect was associated with disruption of FCs 
and peripheral segregation of the UBF, suggesting that 
MXD1 localization in FCs correlates with ongoing rRNA 
synthesis and raising a possible role of this transcription 
factor in the regulation of rDNA transcription.
Interaction between MXD1 and UBF 
As UBF and MXD1 co-localized in the FCs of 
nucleolus, we asked whether MXD1 and UBF interacted 
in the nucleolus. We first performed immunoprecipitation 
assays in HeLa cells. The cells were deprived from serum 
for 48 h to augment MXD1 expression and the lysates 
were immunoprecipitated with anti-UBF antibodies. 
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Figure 1: Endogenous MXD1 localizes in the nucleolus. (A) MXD1 protein expression in growing cells from different cell 
lines used in this work. MXD1 levels were analyzed by immunoblot in the indicated cell lines (left panel). The right panel shows MXD1 
expression in HeLa cells deprived of serum for 48 h. The expression of β-tubulin or α-actin levels were determined as a control for 
protein loading. (B) MXD1 localization in the nucleolus. Cells from the indicated human cell lines and rat sensory neurons were double 
immunolabelled for MXD1 (red) and UBF (green). MXD1 showed a nuclear distribution, including the nucleolus where colocalized with 
UBF. Scale bars: 5 µm.
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Figure 2: MXD1 expression in rat primary cells. (A) Immunofluorescence for MXD1 in sensory neurons and seminiferous tubes. 
In dissociated neurons from rat sensory ganglion MXD1 appeared concentrated in the nucleolus and in nucleoplasmic microfoci. Within the 
nucleolus, MXD1 aggregated in numerous large foci with the typical pattern of FCs. The prominent neuronal nucleolus is clearly identified 
by the accumulation of rRNAs stained with PI. Dissociated cells from seminiferous tubes illustrated numerous spermatogonia, with an 
intense nuclear signal of MXD1, and several Sertoli cells with a nucleolar pattern of MXD1 immunoreactivity (arrows). Co-staining with 
PI revealed the typical tripartite structure formed by the Sertoli cell nucleolus and two associated masses of perinucleolar heterochromatin 
(arrowheads). Scale bars: 10 µm. (B) Immunogold electron microscopy of MXD1 in a neuronal nucleolus. Tissue fragments from sensory 
ganglion were immunolabeled with the anti-MXD1 antibody and then with a secondary antibody conjugated with 10 nm gold particles. 
Immunogold particles decorated fibrillar centers (arrows) and some particles were also observed in the associated dense fibrillar component. 
Scale bar: 250 nm. Inset. Higher magnification of a fibrillar center (FC) surrounded by the dense fibrillar component (DFC). Note the 
immunolabeling of the FC. Scale bar: 150 nm. No immunogold particles were detected in control samples without primary antibody.
Figure 3: Ectopic MXD1 localizes in nucleoli. (A) Nucleolar localization of transfected MXD1. HeLa cells transfected with the 
GFP, GFP-MNT and GFP-MXD1 constructs (green). Whereas GFP-MXD1 protein localized in the nucleolus, GFP-MNT showed a nuclear 
staining but was absent from the nucleolus. (B) HeLa cells were transfected with the GFP-MXD1 construct and 24 h after transfection 
immunofluorescence was performed for endogenous UBF as described in Figure 1 with a secondary antibody conjugated with Texas Red. 
Nuclei were stained with DAPI (blue). The images were acquired by confocal (A) or epifluorescence (B) microscopy. Scale bars: 5 µm.
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Immunoblot analysis showed that MXD1 was present 
in the immunoprecipitates, indicating a UBF-MXD1 
interaction (Figure 6A). Similar results were obtained 
in cells transfected with UBF-Flag expression vector 
(not shown). Next, we asked whether this interaction 
takes place in the nucleoli of the cells. To analyse this, 
we performed an in situ proximity ligation assay (PLA) 
in HeLa cells. As shown in Figure 6B in situ PLA signal 
was positive with antibodies against MXD1 and UBF. 
This interaction was higher in discrete areas of the nuclei, 
likely corresponding to the nucleoli. No interaction was 
detected in the cytoplasm, serving as a negative control. 
Interaction was also observed between MYC and MAX 
(positive control), but no signal was detected when we 
performed the assay with antibodies against MXD1 
or UBF and hemoglobins (negative controls). Signal 
quantification indicated that MXD1 and UBF interact but 
less than MYC-MAX (Figure 6C). Taken together, these 
results suggest that MXD1 and UBF are interacting at the 
site of the rRNA synthesis in the nucleolus.
As MXD1 localized in the FCs of nucleoli, we 
hypothesized that it might be taking part in the regulation of 
rRNA synthesis. We first asked whether MXD1 was bound 
to the rRNA genes. The human rRNA genes are organized 
Figure 4: Nucleoplasmic but not nucleolar localization of MYC and MNT. (A) Cells from the cell lines indicate at the left 
were co-immunostained for UBF and MYC or MNT. Confocal merged images show the lack of co-localization of MYC and MNT with the 
nucleolus in all cell lines. Scale bars: 5 µm.
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in clusters of ~43 kb repeats in tandem distributed among 
five different chromosomes (chromosome number 
13, 14, 15, 21 and 22). We performed a chromatin 
immunoprecipitation assay (ChIP) of MXD1 on the rDNA 
in HeLa cells. We studied MXD1 binding to regions already 
analysed for MYC binding [27] in the transcribed region 
and in the intergenic spacer (Figure 7A). We performed this 
analysis in the chromatin of HeLa cells after 48 h of serum 
deprivation, in order to increase the levels of MXD1. As 
negative controls, we tested two amplicons mapping in the 
long arm of chromosomes 13 and 15 (i.e., the opposite arm 
to where rDNA genes map). The results showed that MXD1 
was bound throughout the entire rDNA repeat, in the 
same regions already reported as bound to MYC [27, 28] 
(Figure 7B). As a positive control, we performed ChIP 
analysis for UBF, which bound to the rDNA transcribed 
regions (H1, H4, H8) and less in the IGS (H18, H27, H42) 
[27, 29] (Figure 7B). As expected, UBF binding was much 
stronger than that of MXD1. Similar results were found in 
HEK293T cells (Supplementary Figure S3).
It is established the effect of MYC as a positive 
regulator of RNA pol I [27, 30–32] and it has also been 
Figure 5: Nucleolar segregation of MXD1 by actinomycin D treatment. Control and actinomycin D-treated cells (50 ng/ml 
for 1 h) from HS181 and MSC-3H cell lines were co-immunostained for MXD1 and UBF. In control HS181 and MSC-3H cells, MXD1 
colocalizes with UBF in nucleoli. Inhibition of nucleolar transcription with actinomycin D induces depletion of MXD1 in HS181 nucleoli. 
In actinomycin D-treated MSC-3H cells, both MXD1 and UBF appear segregated at the nucleolar periphery as juxtaposed perinucleolar 
caps. In a control rat sensory ganglion neuron, UBF and MXD1 colocalize in numerous fibrillar centers. In contrast, fibrillar centers tend 
to disappear and MXD1 and UBF segregate upon systemic actinomycin D (Act.D) treatment (300 µg/k for 3 h). Thus, whereas MXD1 
segregates as a thin ring around of both the nucleolus and smaller nucleolar fragments and colocalizes with UBF in residual fibrillar centers, 
the bulk of UBF tends to segregate as a large mass at the nucleolar periphery.  Scale bars: 5 µm.
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Figure 6: MXD1 and UBF interaction. (A) Co-immunoprecipitation of MXD1 and UBF in lysates of HeLa cells. Cells were serum-
deprived for 48 h and immunoprecipitation of UBF was performed, followed by immunoblot against MXD1 and UBF. (B) In situ PLA in 
growing HeLa cells to test MXD1-UBF interaction. The pairs of antibodies used were anti-MXD1 and anti-UBF, anti-MYC and anti-MAX 
(positive control), anti-MXD1 and anti-ɣ-Hemoglobin (ɣHB) (negative control) and anti-UBF and anti-β-hemoglobin (negative control). 
Red dots showed the MXD1-UBF interaction. DAPI staining of DNA was used to detect cell nuclei. Scale bars: 5 µm. (C) Quantification of 
PLA signals. PLA positive signals per nuclei were quantified using ImageJ software. At least 200 nuclei were counted for each experimental 
condition. Data are mean ± s.e.m **P < 0.01.
Figure 7: MXD1 binding to rDNA chromatin. (A) Schematic representation of a rDNA repeat showing the sequences of the three 
mature rRNAs (grey boxes), the introns (thick line) and the intergenic region (IGS, thin line). The grey bar represents the amplicon used 
for pre-rRNA determination by RT-qPCR. (B) ChIP of MXD1 and UBF in HeLa cells deprived of serum for 48 h. The amplicons H1-H42 
cover different regions of the rDNA gene and intergenic regions [27]. Data are mean values from four ChIP experiments. The inset shows 
the signals of UBF in the H18-H42 amplicons.
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reported that MXD1 down-regulates rRNA synthesis 
throughout the repression of UBF expression in 
fibroblasts [33]. We analyzed in our models whether MXD1 
down-regulates rDNA transcription. We transfected 
the K562 cells with siRNA against MXD1 and at 72 h 
post-transfection we counted the cells and prepare protein 
lysates and total RNA. We confirmed a decrease in MXD1 
protein levels in cells transfected with the siRNA, whereas 
UBF levels did not change (Figure 8A, left panel). 
We also tested the effect of MXD1 overexpression 
on UBF levels. Cell were transduced with lentivirus 
containing the GFP-MXD1 gene and 5 days after the 
levels of UBF were determined by immunoblot. The 
results showed no significant changes in UBF levels upon 
MXD1 overexpression (Figure 8A, right panel). Next, we 
determined the amounts of total RNA per cell in MXD1 
knock-down and in the control cells. Since rRNA accounts 
for approximately 80% of total RNA in the cell [20], we 
assumed that if there was a change in total RNA levels 
it would be mainly due to ribosomal RNA. As shown 
in Figure 8B, MXD1 knock-down in K562 cells led to 
a higher amount of total RNA in the cell as compared 
with controls. This tendency was observed in the four 
experiments performed, although the difference with the 
control cells was not statistically significant (P = 0.37). 
Next we determined the levels of pre-rRNA (45S rRNA) 
which is the primary and unstable product of RNA pol 
I transcription, in MXD1-silenced K562 cells. pre-RNA 
was measured by RT-qPCR using 45S rRNA specific 
primers and the results showed higher levels of 45S rRNA 
in cells with decreased MXD1 levels (Figure 8C). We also 
determined the pre-rRNA levels in HeLa cells transfected 
Figure 8: Effect of MXD1 depletion on rRNA levels. (A) Left panel: K562 were transfected with MXD1 siRNA or control siRNA. 
72 h after transfection, MXD1 and UBF levels were analysed by immunoblot. Right panel: K562 were infected with GFP-MXD1 lentivirus 
or empty vector lentivirus (E.V.). 5 days after infection MXD1 and UBF levels were analysed by immunoblot. The levels of α-actin were 
determined as a control of protein loading. (B) Total RNA per cell in K562 cells 72 h after MXD1-siRNA transfection. (C) Expression of 
45S pre-rRNA upon MXD1 knock-down in K562 cells. Cells were transfected with MXD1 siRNA and 72 h after transfection the RNA was 
analyzed by RT-qPCR. Data are mean ± s.e.m. from four independent transfections. (D) Expression of 45S pre-rRNA upon MXD1 knock-
down in HeLa cells. Cells were transfected with a MXD1 short-hairpin vector and after 15 days of selection with puromycin, RNA was 
prepared and the expression of 45S pre-rRNA was analyzed by RT-qPCR. Data are mean values from two independent transfections ± s.e.m. 
The depletion of MXD1 protein was confirmed by immunoblot (upper panel). (E) Nascent EU-labelled rRNA after a 15 min EU pulse in 
K562 cells transfected with MXD1 siRNA. Signals from 100 cells were quantified using ImageJ software. Two representative cells are 
shown in the bottom panel. Scale bars: 5 µm. Error bars are s.d. **P < 0.001.
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with sh-MXD vector. The decrease in MXD1 protein 
was confirmed by immunoblot (Figure 8D, upper panel). 
The results showed an elevation of 45S pre-rRNA upon 
MXD1 silencing (Figure 8D, lower panel). Finally, we 
tested the rate of the novo rRNA synthesis with pulses 
of 5-ethynyluridine (EU). The increased rRNA synthesis 
upon MXD1 depletion in K562 was also observed 
after labelling this EU incorporation in nascent rRNA 
with an azide-containing Alexa Fluor594 fluorophore 
(Figure 8E). In a complementary approach, we tested 
the effect of MXD1 enforced expression on rRNA 
synthesis. HeLa and HEK293T cells were transfected 
with a GFP-MXD1 expression vector, and MSC-3H cells 
were transduced with GFP-MXD1 lentiviral particles. In 
the three cell lines GFP-MXD1 was overexpressed 48 h 
after transfection as shown by immunoblot (Figure 9A). 
De novo RNA synthesis was determined by EU pulse 
labelling. The EU signals revealed that those cells with 
MXD1 overexpression showed a reduced RNA synthesis 
with respect to controls (Figure 9B, 9C). The EU labelling 
Figure 9: Effect of MXD1-enforced expression on rRNA synthesis. (A) Overexpression of GFP-MXD1 protein after transfection 
of GFP-MXD1 in HeLa and HEK293T, and lentiviral transduction of MSC-3H cells. The GFP-MXD1 protein was detected by immunoblot 
48 h after transfection or virus infection. α-actin levels were determined as a control for protein loading. (B) Nascent EU-labelled rRNA 
after a EU pulse of 45 min in the indicated cell lines transfected with an expression vector for GFP-MXD1 or the empty vector (E.V., 
pReceiverLv103 vector). Error bars are s.d. **P < 0.001. (C) Representative images showing a transfected (GFP-positive) cell and several 
untransfected cells. Note the accumulation of GFP-MXD1 in the nucleoli and the reduced EU labelling (arrows). Representative confocal 
merged images of HEK293T and MSC-3H cells showing GFP-MXD1 (green) and EU-labelled RNA (red). Scale bars: 10 µm.
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in the cells transfected or transduced with the empty 
vector was similar than in the non-transfected cells 
(not shown).
DISCUSSION
In this work we report that MXD1 localizes within 
the nucleolus and binds UBF and rDNA chromatin. 
These novel findings open new biological activities for 
MXD1. Nucleolar localization of endogenous MXD1 was 
observed in growing cells from different tissues origins 
(carcinoma, leukemia, embryonic stem cells) as well 
as in primary post-mitotic cells as neurons and Sertoli 
cells. MXD1 accumulates in the nucleolus although 
it is also present in the nucleoplasm. However, it is of 
note that MXD1 nucleolar localization was observed 
for endogenous MXD1 in proliferating cells, where it is 
expressed at relative low levels, as compared to quiescent 
cells. Moreover, when MXD1 levels were elevated 
after transfection, the MXD1 was strongly accumulated 
in nucleoli. In contrast, overexpressed MNT, another 
member of the MXD family, did not accumulate in 
nucleoli, supporting the specific nucleolar localization 
of MXD1. Previous reports have also described a 
nucleolar localization for MYC when expressed at supra-
physiological levels or upon treatment with proteasome 
inhibitors [27, 31, 34]. In contrast, in our experiments we 
have analysed basal MYC levels in proliferating cells. 
In this setting MYC is present in the nucleoplasm and 
excluded from the nucleoli in the cell lines under analysis. 
Nucleolar localization of MXD1 led us to explore 
the possibility of an involvement of MXD1 in rRNA 
synthesis, the major biological role of nucleolus. In fact, 
by immunofluorescence MXD1 concentrates in FCs and 
by immunogold electron microscopy MXD1 distributes 
in FCs and associated DFC, two functionally linked 
structures -the FC/DFC unit- where rDNA transcription 
and initial steps of rRNA processing take place [17, 35].
In fact, inhibition of RNA pol I transcription with 
a low concentration of actinomycin D, which induces 
peripheral segregation of both the rRNA genes and UBF 
[36], also redistributes MXD1 at the periphery of the 
nucleolus. This suggests that MXD1 and UBF remain 
associated with inactive rRNA genes. In this vein, it has 
been already reported that MXD1 downregulates rRNA 
synthesis through MXD1-dependent downregulation 
of UBF in mouse fibroblasts [33]. We have confirmed 
the MXD1-dependent downregulation of rRNA 
synthesis. However, in K562 cells we could not detect a 
significant change in UBF levels upon MXD1 depletion 
or overexpression. Therefore, in our model MXD1 
must impair rRNA synthesis through an alternative 
mechanism, although a small effect on UBF may 
persist. It is conceivable that MXD1 impairs UBF 
function in rDNA transcription through the MXD1-UBF 
interaction. Actually, the fact that MXD1 binds not only 
the promoter but also the IGS in the rDNA chromatin 
supports an indirect involvement of MXD1 in the rDNA 
transcription regulation rather than a direct repressive 
effect upon binding to E-boxes. So it cannot be ruled 
out the possibility that MXD1 binds to rDNA through 
another DNA-bound protein. The detailed molecular 
mechanisms of this interaction require further work to 
be unveiled.
The ability of MYC to stimulate ribosome 
biogenesis is critical for the orchestration of the processes 
of cell cycling and energy production required for 
proliferation of cancer cells [37]. Our work suggests 
that MXD1 antagonizes MYC in its positive regulation 
of rRNA synthesis. rRNA and ribosomal protein 
synthesis contribute to MYC oncogenic activity. Indeed, 
the inhibition of MYC activity on RNA pol I has been 
proposed as a therapeutic target [38]. We hypothesize that 
a major role of MXD1 could be to curb excessive MYC 
activity on ribosome biosynthesis and cell growth. Further 
work is required to demonstrate these hypotheses.
MATERIALS AND METHODS 
Cell culture transfections and lentiviral 
transduction
Human K562 chronic myeloid leukemia, HEK293T 
embryonic kidney and HeLa cervical cancers cells, were 
from ATCC and grown in RPMI (K562) or DMEM (other 
cell lines) with fetal calf serum and antibiotics. MSC-3H 
cells, transformed human mesenchymal stem cells, 
were grown as described [39]. Human embryonic stem 
cells HS181 [40] were grown using mTeSR1 medium 
(StemCell Technologies) on Geltrex-coated plates 
(ThermoFisher). Transient transfections were carried out 
using the jetPEI reagent (Polyplus Transfection) or with 
Ingenio Electroporation solution (Mirus) in an Amaxa 
nucleofector. For lentivirus production, HEK293T cells 
were transfected using the jetPEI reagent method with 
virion packaging vectors (pCMV-VSV-G and psPAX2) 
and the GFP-MXD1 lentiviral construct or its empty vector 
in a ratio amount of 1:3:4 respectively. Two days after 
transfection, supernatant containing lentiviral particles 
was collected and filtered through 0.45 μm pore size filters 
(Merck Millipore). Viral particles were concentrated by 
precipitation using PEG8000 and resuspended in serum-
free DMEM. K562 and MSC-3H cells were infected 
with a MOI of 2 in presence of 5 μg/ml of polybrene for 
48 h. The plasmids and siRNAs used are described in 
Supplementary Table S1
Immunoblot and immunoprecipitation
Cell lysis, immunoblots and immunoprecipitations 
were performed as described elsewhere [41]. The primary 
antibodies used are described in Supplementary Table S2 
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and the immunoblots were revealed with an Odyssey 
scanner (Li-Cor Biosciences).
Immunofluorescence and immunogold staining 
Tissue fragments from rat testes and trigeminal 
ganglion were fixed with 4% paraformaldehyde in PBS. 
Squash preparations from both tissues were processed and 
immunostained as reported previously [23]. The protocol 
was approved by the Ethics Committee of the University 
of Cantabria. Adherent cells grown on glass coverslips 
and were fixed with 4% paraformaldehyde in PBS for 
15 min at room temperature. Fixed cells were washed 
with PBS and permeabilized with 1% Triton X-100 in 
PBS during 30 min. Then, cells were treated with blocking 
buffer (3% BSA; 0.1% Triton X-100 in PBS) for 20 min, 
washed with PBS and 0.1% Triton X-100 in PBS, and 
incubated overnight at 4ºC with the primary antibodies 
diluted in blocking buffer. The slides were incubated for 
1 h at room temperature with the secondary antibody 
conjugated with FITC or Cy3 (Jackson Laboratories). 
The samples were mounted with ProLong Gold Antifade 
mountant (LifeTechnologies). Confocal images were 
obtained with a Leica TCS SP5 microscope and processed 
using Adobe Photoshop and ImageJ (http://rsb.info.nih. 
gov/ij/) softwares. For immunogold electron microscopy, 
tissue fragments from sensory ganglion were fixed with 
4% paraformaldehyde and embedded in Lowicryl 4 M. 
Ultrathin sections were immunolabeled with the anti-
MXD1 antibody and then with a secondary antibody 
conjugated with 10 nm gold particles The antibodies used 
are described in the Supplementary Table S2.
In situ proximity ligation assay
In situ Proximity Ligation Assay (PLA) was 
performed with Duolink in situ Red Starter kit Mouse/
Rabbit (Sigma-Aldrich) according to manufacturer’s 
instructions with home-made buffers as previously 
described [41]. In situ PLA positive signals were 
quantified using the ImageJ software. At least 200 nuclei 
were measured for each experimental condition. Cell 
samples were visualized using a confocal microscope 
as described above. The primary antibodies used are 
described in Supplementary Table S2.
RNA analysis
Total RNA was isolated using the RNeasy kit 
(Qiagen). cDNA was generated by reverse transcription 
(RT) using the iScript (Bio-Rad). Quantitative polymerase 
chain reaction (qPCR) was performed with specific 
primers (Supplementary Table S3) using the iQSYBR 
Green supermix (Bio-Rad). Labelling of rRNA with 
5-ethynyluridine (EU) was performed with the Click-iT 
RNA AlexaFluor594 kit (ThermoFisher) for 15 min (K562 
cells) or 50 min (HeLa, HEK293T and MSC-3H cells) 
and assessed by microscopic imaging. Levels of mRNA 
and pre-rRNA were normalized against actin and RPS14 
mRNA levels.
Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) 
was performed essentially as described [41]. 
Immunoprecipitated DNA was purified with the QIAquick 
PCR Purification Kit (Qiagen) and analysed by qPCR. The 
antibodies and primers used are described in Table 2 and 
Table 3 respectively.
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